pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

hotspot-therapeutics PRESS RELEASE ARCHIVE

Sep 27, 2023

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting

Apr 19, 2023

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023

Apr 11, 2023

HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B

Mar 14, 2023

HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023

Jan 3, 2023

HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B

Dec 6, 2022

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

Nov 10, 2022

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Oct 5, 2022

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting

Jul 25, 2022

HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer

Jul 19, 2022

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

May 26, 2022

Excelra faz parceria com a HotSpot Therapeutics para aprimorar os esforços da descoberta de medicamentos alostéricos Brazil - Português USA - English India - English USA - Français USA - español USA - Deutsch Latin America - español

May 25, 2022

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts USA - English USA - English France - Français España - español Deutschland - Deutsch Brazil - Português Latin America - español

Apr 8, 2022

HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

Mar 8, 2022

HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

Feb 17, 2022

HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series

Jan 10, 2022

HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets

Nov 29, 2021

HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic

Nov 16, 2021

HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Nov 9, 2021

HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting

Oct 12, 2021

HotSpot Therapeutics to Present at the Solebury Trout /BMO Fall Private Company Showcase

Apr 14, 2021

HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer

May 21, 2020

HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines

Aug 23, 2019

HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.

Oct 30, 2018

HotSpot Therapeutics Expands Board of Directors and Management Team

Jul 17, 2018

HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery

Google Analytics Alternative